Two Sigma Investments LP Purchases 131,916 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI)

Two Sigma Investments LP increased its stake in Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) by 266.2% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 181,471 shares of the biopharmaceutical company's stock after buying an additional 131,916 shares during the period. Two Sigma Investments LP owned 0.37% of Puma Biotechnology worth $553,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. SG Americas Securities LLC raised its stake in shares of Puma Biotechnology by 83.9% in the fourth quarter. SG Americas Securities LLC now owns 24,668 shares of the biopharmaceutical company's stock worth $75,000 after purchasing an additional 11,252 shares during the last quarter. Wells Fargo & Company MN raised its position in Puma Biotechnology by 36.5% in the 4th quarter. Wells Fargo & Company MN now owns 22,929 shares of the biopharmaceutical company's stock worth $70,000 after buying an additional 6,126 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in Puma Biotechnology by 19.5% during the 4th quarter. Bank of New York Mellon Corp now owns 331,853 shares of the biopharmaceutical company's stock valued at $1,012,000 after acquiring an additional 54,150 shares during the period. American Century Companies Inc. lifted its stake in Puma Biotechnology by 8.4% during the 4th quarter. American Century Companies Inc. now owns 948,376 shares of the biopharmaceutical company's stock valued at $2,893,000 after acquiring an additional 73,833 shares during the period. Finally, JPMorgan Chase & Co. boosted its holdings in shares of Puma Biotechnology by 182.3% during the 4th quarter. JPMorgan Chase & Co. now owns 136,897 shares of the biopharmaceutical company's stock valued at $418,000 after acquiring an additional 88,404 shares during the last quarter. Hedge funds and other institutional investors own 61.29% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on PBYI shares. HC Wainwright restated a "buy" rating and set a $7.00 price objective on shares of Puma Biotechnology in a research report on Friday, February 28th. Wall Street Zen upgraded shares of Puma Biotechnology from a "buy" rating to a "strong-buy" rating in a research note on Thursday, May 22nd.

Puma Biotechnology Price Performance

PBYI stock traded up $0.02 during trading on Thursday, reaching $3.56. The company's stock had a trading volume of 164,977 shares, compared to its average volume of 444,685. The company's fifty day moving average is $3.15 and its 200-day moving average is $3.11. Puma Biotechnology, Inc. has a 1 year low of $2.23 and a 1 year high of $4.13. The company has a market capitalization of $176.69 million, a P/E ratio of 7.42 and a beta of 1.29. The company has a quick ratio of 1.40, a current ratio of 1.42 and a debt-to-equity ratio of 0.46.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.